Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $1,052.90 Consensus PT from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned an average recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $1,052.90.

A number of analysts have recently weighed in on the stock. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Bank of America reaffirmed an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Royal Bank of Canada lowered their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $714.47 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a fifty-two week low of $693.00 and a fifty-two week high of $1,211.20. The business has a 50 day moving average price of $803.10 and a two-hundred day moving average price of $988.80. The firm has a market cap of $78.51 billion, a PE ratio of 17.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.08.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the period. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Finally, Family Firm Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.